Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that causes long-lasting inflammation and ulcers (sores) in the innermost lining of the large intestine (colon and rectum).
Ranked by community outcomes, then evidence grade, Health Voice mentions, and recency.
Why it may help Ulcerative Colitis: Improves disease activity
Why it may help Ulcerative Colitis: Repairs colon lining
Elimination diet restricting fermentable carbohydrates (FODMAPs) shown to reduce IBS symptoms in most patients.
Why it may help Ulcerative Colitis: Vitamin D may modulate immune responses and reduce inflammation in the gut, potentially alleviating symptoms and supporting mucosal healing in individuals with ulcerative colitis.
Why it may help Ulcerative Colitis: Reduces UC severity
Wheatgrass is a nutrient-dense food derived from young wheat shoots, often consumed for its purported antioxidant and anti-inflammatory benefits, though scientific evidence for specific health claims is limited.
Wormwood is a bitter botanical traditionally used for digestive complaints. Recent literature notes its use in addressing persistent symptoms attributed to Lyme disease, though rigorous clinical evidence for many indications is limited.
Amino acid that supports intestinal barrier integrity; studied for post-infectious IBS-D.
Deglycyrrhizinated licorice for ulcers and GERD without BP effect.
Why it may help Ulcerative Colitis: Butyrate serves as a primary energy source for colonocytes and possesses anti-inflammatory properties, which can promote gut barrier integrity and reduce inflammation in ulcerative colitis.
Zinc carnosine is a chelated mineral form studied for its roles in mucosal integrity and immune support. Research highlights its importance in addressing deficiencies linked to inflammatory and malabsorptive conditions.
Why it may help Ulcerative Colitis: Reduces colonic inflammation
Why it may help Ulcerative Colitis: Often deficient
Demulcent herb (Ulmus rubra) traditionally used to soothe GI mucosa.
Mucilaginous herb soothing GI and respiratory mucosa.
Why it may help Ulcerative Colitis: Curcumin maintains remission
Why it may help Ulcerative Colitis: VSL#3 induces and maintains remission
Why it may help Ulcerative Colitis: Omega-3 fatty acids, particularly EPA and DHA, exert anti-inflammatory effects by modulating eicosanoid pathways and cytokine production, which can reduce gut inflammation in ulcerative colitis.
Inner-leaf aloe juice traditionally used for digestion, gut healing, and as a soothing tonic; also reported to support thyroid health.
Community outcomes
Self-reported by community members · not medical advice.
Self-reported community outcomes. Not medical advice. Requires at least three reports per remedy to surface.
Community outcome data is still being collected for this ailment.
Be the first to share your experience →As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.
Structured experience reports from people managing this condition. Not medical advice.
You can share without an account — we'll send a one-time code to verify your email. Or sign in.
Loading posts…
Community Discussions
How global health authorities view Ulcerative Colitis.
The Mayo Clinic acknowledges that while diet doesn't cause UC, certain foods can worsen symptoms during flares. They suggest identifying trigger foods and working with a dietitian. The NCCIH notes that some complementary health approaches, like probiotics, have shown promise for IBD, but more research is needed. They also emphasize the importance of discussing any complementary therapies with a healthcare provider. The NHS advises on dietary adjustments to manage symptoms and highlights the role of stress management. Cochrane reviews have examined various interventions for UC, including probiotics and omega-3s, often concluding that while some show potential, more high-quality evidence is needed to make definitive recommendations.
Indexed studies for Ulcerative Colitis, grouped by source type and quality.
Filter by source type
Pooled analyses across multiple human trials.
Shehab M, Hassan A, Alrashed F, Abbas A, Ma C, Narula N · Inflammatory bowel diseases · 2025
Ulcerative colitis (UC) is a chronic disorder with a considerable negative impact on health-related quality of life (HRQoL), which has been recently recognized as an important treatment target. The purpose of this study is to compare the efficacy of different biologics and small molecule therapies in achieving better patient-reported outcomes and HRQoL in patients with UC. We performed a systematic review and network meta-analysis of the EMBASE, MEDLINE, and Cochrane Central databases from inception until February 1, 2024. The primary endpoint was clinical remission in the patient-reported outcome (PRO-2) score in UC patients who were treated with different biologics or small molecules during induction and maintenance phases. PRO-2 score is the sum of both stool frequency and rectal bleeding subscores. The secondary outcome was improvement of HRQoL defined as an increase in Inflammatory Bowel Disease Questionnaire score of ≥16 points from baseline or any change in total score f
Dai Y, Yang W, Xu L, Pan P, Liu S, Sun Y · Pharmacology research & perspectives · 2025
Ongoing evaluations of targeted therapies for moderate-to-severe ulcerative colitis (UC) continue to unfold, with the emergence of novel drugs. However, head-to-head trials comparing these therapies are still lacking. The aim of this study is to investigate the therapeutic effects of targeted therapies in moderate-to-severe UC. The Cochrane Library, Web of Science, PubMed, and Embase were searched from the inception to November 12, 2024. Statistical analyses included multivariate random effects models and Bayesian modeling. Stratified and sensitivity analyses were also performed. Publication bias was assessed using funnel plots. Outcomes such as clinical response/remission, endoscopic remission, mucosal healing, quality of life, adverse events (AEs), and serious adverse events (SAEs) were used to quantify the relative therapeutic effects. Thirty-three studies (33 reported on the induction phase; 13 reported on the maintenance phase) were identified. In the induction phase, Upadacitinib
Shehab M, Alrashed F, Alsayegh A, Aldallal U, Ma C, Narula N · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · n=270
Treatment options for moderate to severe ulcerative colitis (UC) are increasing rapidly, but the lack of comparative efficacy trials makes treatment choices a clinical challenge. This network-meta-analysis aimed to compare the relative efficacy of biologics and small molecules in achieving remission in patients with moderate to severe UC. The literature was searched up to May 2024. Phase 3 placebo or active comparator randomized controlled trials were included. The primary outcome was induction and maintenance of endoscopic improvement (Mayo Endoscopic Score [MES] ≤1). Secondary outcomes were the induction and maintenance of clinical remission, endoscopic (MES = 0) and histological remission. A sub-analysis was performed based on the randomized controlled trial design and previous exposure to biologic therapy. We identified 36 studies that met our inclusion criteria, with 14,270 patients with UC. Upadacitinib ranked highest in inducing clinical remission (99.6%), and endo
Recommendations from medical societies (NICE, AHA, ADA, ACG, Endocrine Society…).
Ulcerative colitis: management
NICE · Strength: null
This guideline covers diagnosing and managing ulcerative colitis in adults, young people, and children. It aims to improve care from initial diagnosis through to long-term management.
Cohort, case-control, and cross-sectional human studies.
Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN · Gastroenterology · 2024
We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological Association (AGA) Clinical Guidelines on the management of moderate-to-severe ulcerative colitis (UC). We searched multiple electronic databases through November 21, 2023, to identify randomized controlled trials in adults with moderate-to-severe UC, comparing different advanced therapies (tumor necrosis factor antagonists, vedolizumab, sphingosine-1-phosphate receptor modulators, interleukin 12/23 or selective interleukin 23 antagonists, and Janus kinase [JAK] inhibitors) against placebo or another active comparator. Our primary outcomes were induction and maintenance of clinical remission, and our secondary outcome was endoscopic improvement. We performed a network meta-analysis using a frequentist approach and applied Grading of Recommendations, Assessment, Development and Evaluation (GRADE) to appraise certainty of evidence. After excluding JAK inhibitors as potenti
The Role of Appendicectomy in Ulcerative Colitis: Systematic Review and Meta-Analysis.
Welsh S, Sam Z, Seenan JP, Nicholson GA · Inflammatory bowel diseases · 2023 · n=733
This updated systematic review and meta-analysis investigates the putative role of the appendix in ulcerative colitis as a therapeutic target. Ovid Medline, Embase, PubMed and CENTRAL were searched with MeSH terms ("appendectomy" OR "appendicitis" OR "appendix") AND ("colitis, ulcerative") through October 2020, producing 1469 references. Thirty studies, including 118 733 patients, were included for qualitative synthesis and 11 for quantitative synthesis. Subgroup analysis was performed on timing of appendicectomy. Results are expressed as odds ratio (OR) with 95% confidence intervals (CIs). Appendicectomy before UC diagnosis reduces the risk of future colectomy (OR, 0.76; 95% CI, 0.65-0.89; I2 = 5%; P = .0009). Corresponding increased risk of colorectal cancer and high-grade dysplasia are identified (OR, 2.27; 95% CI, 1.11-4.66; P = .02). Significance is lost when appendicectomy is performed after disease onset. Appendicectomy does not affect hospital admission rates (OR, 0.87; 95% C
Public-health agencies: NCCIH, NIH, CDC, NHS.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Strength: null
Part of the NIH, NIDDK provides detailed, evidence-based information on ulcerative colitis, including symptoms, diagnosis, treatments, and living with the condition.
Registered ongoing or completed trials (ClinicalTrials.gov).
n=134 · NCT06660693 · RECRUITING · RECRUITING
This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by infliximab in upadacitinib non-responders is non-inferior to conventional management with infliximab only.
Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis
n=40 · NCT04750135 · UNKNOWN · UNKNOWN
Brief Summary: This is a randomized, controlled study evaluating metformin tablets administered daily for 8 weeks. The purpose of the study is to evaluate the efficacy and safety of metformin in the treatment of mild to moderately active ulcerative colitis. Disease activity will be measured using Mayo score for ulcerative colitis activity. Calculation of the score requires patients to undergo colonoscopy at the start of the study and at week 8.
Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer
n=204 · NCT01091558 · COMPLETED · COMPLETED
The purpose of this study is to look at the importance of L-Arginine in the digestive tract. L-Arginine is an amino acid and is important in making proteins within the cell. The evaluation of colon tissue, blood, urine, diet, health history, and symptoms will help us learn more about L-Arginine and ulcerative colitis. The investigators believe these studies will provide new insights into the treatment for Inflammatory Bowel Disease (ulcerative colitis) and nutritional needs. The investigators plan to enroll 200 participants in this study over the next two years.
Curated cross-source summaries (TRIP Database and similar).
TRIP Database: Search for Ulcerative Colitis
TRIP Database
The TRIP Database is a clinical search engine designed to allow users to quickly and easily find high-quality research evidence to support their practice. This link provides search results for Ulcerative Colitis.
Conventional medical treatment for ulcerative colitis typically involves medications such as aminosalicylates, corticosteroids, immunomodulators, and biologics to reduce inflammation and induce remission. In severe cases or when medical therapy fails, surgery (colectomy) may be considered. Regular monitoring by a gastroenterologist is crucial for managing the disease and preventing complications.
Latest News
Health Videos
This information is for educational purposes only and should not replace professional medical advice. Ulcerative colitis is a serious condition requiring ongoing medical care. Always consult with a qualified healthcare provider before making any decisions about your health or treatment plan, especia
Found something that helped your ulcerative colitis?
Help others see what actually works.
Found something that helped your ulcerative colitis?
Real-world results help others choose what's worth trying.